Nine years of Experience with the Sentinel Lymph Node Biopsy in a Single Italian Center: A Retrospective Analysis of 1,050 Cases

Abstract

Cancer characteristics represent important predictive factors for SLNB positivity, as well as for axillary recurrence in patients with negative SLNB, independently, by surgical and nonsurgical treatment. Therefore, cancer biological behavior and the patient's hormonal profile should be evaluated with care to better tailor the follow-up of women with breast cancer.

Surgical and oncological outcomes of free dermal fat graft for breast reconstruction after breast-conserving surgery

“…5,15 In fact, most of the recurrences in breast cancer occur between the 3 rd and the 6 th year of follow-up. 16 However, recent studies analyzing the oncological outcome of autologous fat grafting have declared this procedure to be safe even with a shorter mean follow-up than ours (<21 months of follow-up vs 34 months). 15,17 It must be stressed that in all aspects considered in the current literature, so far nothing has demonstrated the worsening of oncological outcomes as a result of using these techniques.…”

Localization of metastasis within the sentinel lymph node biopsies: a predictor of additional axillary spread of breast cancer?

“…The need for CALD is generally highly considered for young patients, but in our study, as well as in previous reports this does not seem to be a risk factor for additional metastasis 14,22,23 . However, young age is associated with a higher proportion of positive SLN 24 .…”

Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer

“…Among tumor characteristics we considered: histological type, TNM classification and stage, eventual loco-regional extra-axillary lymph node involvement (internal mammary chain and subclavear), nuclear grading, Mib1/Ki-67 proliferation index, estrogen and progesteron receptors expression, Her2/neu status, and molecular subtypes. Moreover, we included other microscopical histological characteristics which are included in the more recent classification purposed by Veronesi and colleagues (Arnone et al 2010 ) as previously described (Cedolini et al 2014a , b , c ; Bertozzi et al 2013 ; Bernardi et al 2012a , b ), including multifocality/multicentricity, extensive intraductal component, perivascular invasion, peritumoral inflammation, lymph node extra-capsular invasion, and presence of bunched lymph nodes. Finally, we took into consideration also the therapeutic management: type of intervention on the breast (conservative breast surgery or mastectomy) and the axilla (sentinel lymph node biopsy or complete lymph node axillary dissection), eventual neoadjuvant or adjuvant therapies (chemotherapy, hormonal therapy, biological drugs, radiation therapy).…”